G 1/S checkpoint proteins in peripheral blood lymphocytes are potentially diagnostic biomarkers for Alzheimer's disease

Neuroscience Letters

Volumn 526, Issue 2, 2012, Pages

  Song, Juexian ^a   Wang, Shuying ^a   Tan, Mengshan ^a   Jia, Jianping ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Biomarker; Cell cycle; G 1 S checkpoint; Peripheral blood lymphocytes

Indexed keywords

BETA ACTIN; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE 2; CYCLIN E; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; CELL CYCLE PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE SEVERITY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; PARKINSON DISEASE; PATHOGENESIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING; BLOOD; CASE CONTROL STUDY; G1 PHASE CELL CYCLE CHECKPOINT; LYMPHOCYTE; METABOLISM; PATHOPHYSIOLOGY; S PHASE CELL CYCLE CHECKPOINT; SEVERITY OF ILLNESS INDEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; DEMENTIA, VASCULAR; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LYMPHOCYTES; MALE; PARKINSON DISEASE; S PHASE CELL CYCLE CHECKPOINTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84865995136     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.08.020     Document Type: Article

References (28)

1. Bialopiotrowicz E., Kuzniewska B., Kachamakova-Trojanowska N., Barcikowska M., Kuznicki J., Wojda U. Cell cycle regulation distinguishes lymphocytes from sporadic and familial Alzheimer's disease patients. Neurobiology of Aging 2011, 32(12). 2319.e13-26.
2. Chung S.H., Kwon Y.A., Kim H., Shin J.Y., Kim D.K. Dysregulation of cell cycle regulating proteins in peripheral lymphocytes from the patients with Alzheimer's disease. Korean Journal of Psychopharmacology 2004, 15(4):474-479.
3. de las Cuevas N., Urcelay E., Hermida O.G., Saiz-Diaz R.A., Bermejo F., Ayuso M.S., Martin-Requero A. Ca2+/calmodulin-dependent modulation of cell cycle elements pRb and p27kip1 involved in the enhanced proliferation of lymphoblasts from patients with Alzheimer dementia. Neurobiology of Disease 2003, 13(3):254-263.
4. de las Cuevas N., Munoz U., Hermida O.G., Martin-Requero A. Altered transcriptional regulators in response to serum in immortalized lymphocytes from Alzheimer's disease patients. Neurobiology of Aging 2005, 26(5):615-624.
5. Dolman C.L. Diagnosis of neurometabolic disorders by examination of skin biopsies and lymphocytes. Seminars in Diagnostic Pathology 1984, 1(2):82-97.
6. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975, 12(3):189-198.
7. Group TRaNRRIotAAatNIoAW, Consensus report of the Working Group on: Molecular and Biochemical Markers of Alzheimer's Disease The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, Neurobiology of Aging, 19 (2) (1998) 109-116.
8. Hughes C.P., Berg L., Danziger W.L., Coben L.A., Martin R.L. A new clinical scale for the staging of dementia. British Journal of Psychiatry 1982, 140:566-572.
9. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery, and Psychiatry 1992, 55(3):181-184.
10. Inzelberg R., Jankovic J. Are Parkinson disease patients protected from some but not all cancers. Neurology 2007, 69(15):1542-1550.
11. Janoshazi A., Sellal F., Marescaux C., Danion J.M., Warter J.M., de Barry J. Alteration of protein kinase C conformation in red blood cells: a potential marker for Alzheimer's disease but not for Parkinson's disease. Neurobiology of Aging 2006, 27(2):245-251.
12. Lanni C., Racchi M., Mazzini G., Ranzenigo A., Polotti R., Sinforiani E., Oivari L., Barcikowska M., Styczynska M., Kuznicki J., Szybinska A., Govoni S., Memo M., Uberti D. Conformationally altered p53: a novel Alzheimer's disease marker. Molecular Psychiatry 2008, 13(6):641-647.
13. Lu J., Li D., Li F., Zhou A., Wang F., Zuo X., Jia X.F., Song H., Jia J. Montreal cognitive assessment in detecting cognitive impairment in Chinese elderly individuals: a population-based study. Journal of Geriatric Psychiatry and Neurology 2011, 24(4):184-190.
14. Mazzola J.L., Sirover M.A. Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts. Journal of Neurochemistry 2001, 76(2):442-449.
15. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34(7):939-944.
16. Munoz U., Bartolome F., Bermejo F., Martin-Requero A. Enhanced proteasome-dependent degradation of the CDK inhibitor p27(kip1) in immortalized lymphocytes from Alzheimer's dementia patients. Neurobiology of Aging 2008, 29(10):1474-1484.
17. Nagy Z., Esiri M.M., Smith A.D. Expression of cell division markers in the hippocampus in Alzheimer's disease and other neurodegenerative conditions. Acta Neuropathologica 1997, 93(3):294-300.
18. Nagy Z., Esiri M.M., Smith A.D. The cell division cycle and the pathophysiology of Alzheimer's disease. Neuroscience 1998, 87(4):731-739.
19. Nagy Z., Combrinck M., Budge M., McShane R. Cell cycle kinesis in lymphocytes in the diagnosis of Alzheimer's disease. Neuroscience Letters 2002, 317(2):81-84.
20. Petersen R.C., Trojanowski J.Q. Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice. The Journal of American Medical Association 2009, 302(4):436-437.
21. Roe C.M., Behrens M.I., Xiong C., Miller J.P., Morris J.C. Alzheimer disease and cancer. Neurology 2005, 64(5):895-898.
22. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., Amaducci L., Orgogozo J.M., Brun A., Hofman A. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993, 43(2):250-260.
23. Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes and Development 1995, 9(10):1149-1163.
24. Staropoli J.F. Tumorigenesis and neurodegeneration: two sides of the same coin. Bioessays 2008, 30(8):719-727.
25. Tan M., Wang S., Song J., Jia J. Combination of p53(ser15) and p21/p21(thr145) in peripheral blood lymphocytes as potential Alzheimer's disease biomarkers. Neuroscience Letters 2012, 516(2):226-231.
26. Uberti D., Carsana T., Bernardi E., Rodella L., Grigolato P., Lanni C., Racchi M., Govoni S., Memo M. Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients. Journal of Cell Science 2002, 115(Pt 15):3131-3138.
27. Yang Y., Mufson E.J., Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. Journal of Neuroscience 2003, 23(7):2557-2563.
28. Zhou X., Jia J. P53-mediated G(1)/S checkpoint dysfunction in lymphocytes from Alzheimer's disease patients. Neuroscience Letters 2010, 468(3):320-325.